NEW YORK, July 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG). Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=156352&from=4 CLASS PERIOD: March 7, 2024 to March 3, ...

NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/pepgen-inc-lawsuit-submissio ...

Core Viewpoint - A class action securities lawsuit has been filed against PepGen Inc. due to alleged securities fraud affecting investors between March 7, 2024, and March 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that PepGen's lead product candidate, PGN-EDO51, was misrepresented as being more effective and safe than it actually is [2]. - It is alleged that the phase two CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study [2]. - The complaint asserts that the public statements made by the defendants were materially false and misleading throughout the relevant period [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until August 8, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit due to alleged misleading statements about the company's lead product candidate, PGN-EDO51, and its clinical study [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 7, 2024, to March 3, 2025, PepGen's statements regarding PGN-EDO51 were materially false and misleading [3]. - Specific allegations include that PGN-EDO51 was less effective and safe than claimed, and that the phase two CONNECT2 study was dangerous or deficient for FDA approval [3]. - As a result of these issues, it is claimed that PepGen was likely to halt the CONNECT2 study, and the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated [3]. Group 2: Class Action Details - Shareholders are encouraged to register for the class action by the deadline of August 8, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. - There is no cost or obligation for shareholders to participate in this case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its lead product candidate, PGN-EDO51, and its clinical study, CONNECT2 [1][2]. Allegations - The lawsuit claims that during the class period from March 7, 2024, to March 3, 2025, PepGen misrepresented the effectiveness and safety of PGN-EDO51 [1]. - It is alleged that the CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study [1]. - The complaint states that the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated, making the company's public statements materially false and misleading [1]. Class Action Details - Shareholders who purchased shares of PepGen during the specified class period are encouraged to register for the class action by August 8, 2025 [2]. - Registration allows shareholders to receive updates on the case and does not incur any costs or obligations [2]. Law Firm Background - The Gross Law Firm is recognized for its commitment to protecting investors' rights against deceit and fraud, aiming to hold companies accountable for misleading practices [3].

Core Viewpoint - A class action securities lawsuit has been filed against PepGen Inc. due to alleged securities fraud affecting investors between March 7, 2024, and March 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that PepGen's lead product candidate, PGN-EDO51, was misrepresented as being more effective and safe than it actually is [2]. - Allegations include that the phase two CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study [2]. - The complaint asserts that the public statements made by the defendants were materially false and misleading throughout the relevant period [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 8, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit due to alleged misleading statements about the company's lead product candidate, PGN-EDO51, and its clinical study [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from March 7, 2024, to March 3, 2025, PepGen Inc. made materially false and misleading statements regarding PGN-EDO51, claiming it was more effective and safe than it actually was [3]. - It is claimed that the phase two CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study and overstating the product's clinical, regulatory, and commercial prospects [3]. Class Action Details - Shareholders who purchased shares during the specified class period are encouraged to register for the class action, with a deadline of August 8, 2025, to seek lead plaintiff status [4]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle, with no cost or obligation to participate [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit due to allegations of misleading statements related to the company's lead product candidate, PGN-EDO51, and its clinical study [1][2]. Group 1: Allegations and Class Action Details - The class period for the allegations is from March 7, 2024, to March 3, 2025 [1]. - Allegations include that PGN-EDO51 was less effective and safe than claimed, and that the CONNECT2 study was dangerous or deficient for FDA approval [1]. - The lawsuit suggests that PepGen may halt the CONNECT2 study, and that the prospects for PGN-EDO51 were overstated [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by August 8, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

PGN-EDODM1 for DM1 - PGN-EDODM1 targets the pathogenic CUGexp repeats in DM1, aiming to restore correct splicing by liberating MBNL1[29, 30, 31, 32, 33] - In DM1 patient cells, PGN-EDODM1 treatment resulted in a 54% reduction in toxic foci and a 69% correction of mis-splicing[36] - Preclinical studies showed that multiple doses of PGN-EDODM1 led to a 99% correction of myotonia, compared to a single dose[41] - In the FREEDOM Phase 1 trial, a single 10 mg/kg dose of PGN-EDODM1 produced a mean 29% splicing correction[57] PGN-EDO51 for DMD - In a healthy volunteer study, PGN-EDO51 demonstrated exon skipping, with levels reaching 1.4% at Day 10 and 2% at Day 28 in the 15 mg/kg cohort[76] - CONNECT1 study showed that PGN-EDO51 generated encouraging levels of muscle adjusted dystrophin production of 0.70% and total dystrophin production of 0.26% after just 3 months and 4 doses at 5 mg/kg[95] - CONNECT1 study also showed high levels of mean exon 51 skipping of 2.15% after just 3 months and 4 doses at 5 mg/kg[95] EDO Platform - PepGen's EDO platform is designed for nuclear delivery of oligonucleotide therapeutics, showing up to 25X higher nuclear uptake[7, 17, 19] - EDO technology has been shown to increase cellular uptake and endosomal escape up to 24-fold[21]

PGN-EDODM1 for DM1 - PepGen's EDO platform aims to deliver higher levels of oligonucleotide to the nuclei, potentially improving the lives of people with severe neuromuscular and neurological diseases[3] - The FREEDOM-DM1 (Phase 1) trial observed a favorable emerging safety profile and a mean splicing correction of 29% after a single dose of 10 mg/kg at 28 days post-dosing[22] - Preclinical studies showed that multiple doses of PGN-EDODM1 led to greater improvement in splicing correction and myotonia compared to a single dose[35] - In DM1 patient cells, PGN-EDODM1 treatment resulted in a 54% reduction in toxic foci and a 69% correction of mis-splicing[33] - The FREEDOM trial showed a dose-dependent increase in drug tissue concentration, with approximately 12% splicing correction at 5 mg/kg and approximately 29% splicing correction at 10 mg/kg[56] PGN-EDO51 for DMD - The company is voluntarily discontinuing development of PGN-EDO51 for DMD due to the CONNECT1-EDO51 Phase 2 study results not achieving target dystrophin levels[63] - In the CONNECT1-EDO51 trial, a mean maximal exon skipping of 426% (mean increase of 35%) and a mean maximal dystrophin of 059% (mean increase of 036%) were observed after four doses of 10 mg/kg[63] EDO Platform Technology - PepGen's EDO platform is designed to solve the problem of inefficient penetration of muscle cells and the nucleus by naked oligonucleotides[13] - PepGen's EDO platform can result in up to 25X higher nuclear uptake of oligonucleotide[16] - EDO technology has been shown to increase cellular uptake and endosomal escape up to 24-fold[18]